U.S. infectious disease expert Anthony Fauci said it would be clear whether a Covid-19 vaccine was safe and effective by early December, but that more widespread vaccination would not be likely until later in 2021.
Federal health regulators decided to allow the resumption of the U.S. trial of a leading Covid-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported, citing a person familiar with the matter and materials reviewed by it.
The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention presented details about Covid-19 and the requirements for a vaccine in a nine-hour virtual meeting.
Alnylam Pharmaceuticals presented complete results from the company’s ILLUMINATE-B Phase III study in children under 6 years with primary hyperoxaluria type 1 (PH1), a rare disorder affecting the kidneys.
San Diego-based Retrophin is buying Orphan Technologies for $90 million in cash up front and up to $427 million in milestone payments.
Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.
Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
Moderna Inc. completed the enrollment of 30,000 participants in a late-stage study testing the company’s experimental coronavirus vaccine, with over a third of the participants from communities of color.
AstraZeneca’s Covid-19 vaccine accurately follows the genetic instructions programmed into AZD1222 by the developers to successfully provoke a strong immune response, according to a detailed analysis carried out by independent UK scientists.
Researchers called for more research into using blood from recovered Covid-19 patients – or so-called convalescent plasma – as a potential treatment, after a small trial of hospitalized patients in India found it was of no benefit.
